Value and affordability of CAR T-cell therapy in the United States

@article{Fiorenza2020ValueAA,
  title={Value and affordability of CAR T-cell therapy in the United States},
  author={Salvatore Fiorenza and D. Ritchie and S. Ramsey and C. Turtle and J. Roth},
  journal={Bone Marrow Transplantation},
  year={2020},
  pages={1-10}
}
In the United States the increasing number of Food and Drug Administration (FDA)-approved, innovative, and potentially effective commercial cancer therapies pose a significant financial burden on public and private payers. Chimeric antigen receptor (CAR) T cells are prototypical of this challenge. In 2017 and 2018, tisagenlecleucel (Kymriah, Novartis) and axicabtagene ciloleucel (Yescarta, Kite) were approved by the FDA for use after showing groundbreaking results in relapsed/refractory B-cell… Expand

Figures and Tables from this paper

Balancing Quality, Cost, and Access During Delivery of Newer Cellular and Immunotherapy Treatments
TLDR
Various novel approaches to manage challenges in improving access and improving widescale implementation of cellular therapies are described to optimize the access and affordability of the CAR T-cell therapy. Expand
Cancer T-cell therapy: building the foundation for a cure.
TLDR
T-cell cancer therapy has the potential to address target opportunities afforded by its own unique capacity for signal integration and high sensitivity, and an approach that integrates sound reductionist scientific principles with well-informed, thorough preclinical and translational clinical experiments is supported. Expand
CAR-T Cell Therapy for Acute Myeloid Leukemia: Preclinical Rationale, Current Clinical Progress, and Barriers to Success.
TLDR
Key hurdles to the successful introduction of CAR-T cell therapy for the treatment of AML include the effect of antigenic heterogeneity and trade-offs between therapy specificity and sensitivity; on-target off-tumor toxicities; the AML tumor microenvironment; and practical considerations for future trials that should be addressed to enable success. Expand
Effects of the COVID-19 pandemic on publication landscape in chimeric antigen receptor-modified immune cell research
Chimeric antigen receptors (CARs) are artificial receptors introduced mainly into T cells. CAR-induced immune cell (CARi) products have achieved impressive success rates in treating someExpand
Economic Evidence on Potentially Curative Gene Therapy Products: A Systematic Literature Review
TLDR
All gene therapies in this review were shown to be more effective than their comparators, although due to high costs not all were considered cost effective at standard cost-effectiveness thresholds. Expand
Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel
TLDR
Outcomes-based managed entry agreements can play an important role not only in reimbursement, but also in treatment optimisation, however, they are complex to implement and should be the exception and not the rule. Expand
Genetic engineering of T cells for immunotherapy.
TLDR
The principles by which the knowledge of genetics and genome engineering will drive the next generation of adoptive T cell therapies are reviewed. Expand
Nanotraps for the containment and clearance of SARS-CoV-2
TLDR
Nanotraps represent a new nanomedicine for the inhibition of SARS-CoV-2 infection and demonstrated an excellent biosafety profile in vitro and in  vivo. Expand
Engineering microenvironments for manufacturing therapeutic cells
TLDR
This mini-review describes strategies to potentially enhance the expansion of therapeutic cells with biomaterials and bioreactors, as well as to characterize the cell products with microphysiological systems. Expand
Gene therapy: a double-edged sword with great powers
TLDR
It will be seen that with the technology improvement, somatic gene therapy has been proved to be efficient and safe enough for clinical practice, and germline gene therapy should not be put into clinical practice before these issues are solved. Expand
...
1
2
...

References

SHOWING 1-10 OF 100 REFERENCES
The potential impact of CAR T-cell treatment delays on society.
TLDR
The social value ofCAR T is significantly limited by treatment delays, and efficient payment mechanisms, adequate capital, and payment policy reform are urgently needed to increase patient access and maximize the value of CAR T. Expand
Economic Evaluation of Chimeric Antigen Receptor T-Cell Therapy by Site of Care Among Patients With Relapsed or Refractory Large B-Cell Lymphoma.
TLDR
The potential availability of CAR T-cell therapies that are associated with a lower incidence of adverse events and are suitable for outpatient administration may reduce the total costs of care by enabling the use of these therapies in nonacademic specialty oncology networks. Expand
Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma.
TLDR
It is possible that both anti-CD19 chimeric antigen receptor T-cell therapies meet a less than $150,000/QALY threshold, but depends on long-term outcomes compared with chemoimmunotherapy and stem-cell transplantation, which are uncertain. Expand
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.
  • Daniel W Lee, B. Santomasso, +19 authors S. Neelapu
  • Medicine
  • Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2019
TLDR
The goal is to provide a uniform consensus grading system for CRS and neurotoxicity associated with immune effector cell therapies, for use across clinical trials and in the postapproval clinical setting. Expand
Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States
TLDR
Axi-cel is a potentially cost-effective alternative to salvage chemotherapy for adults with R/R LBCL and long-term follow-up is necessary to reduce uncertainties about health outcomes. Expand
Anti‐BCMA CAR T‐Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
TLDR
The initial toxicity profile of a BCMA‐directed cellular immunotherapy for patients with relapsed or refractory multiple myeloma is reported andCAR T‐cell expansion was associated with responses, and CAR T cells persisted up to 1 year after the infusion. Expand
Are CAR-T therapies living up to their hype? A study using real-world data in two cohorts to determine how well they are actually working in practice compared with bone marrow transplants
TLDR
A novel methodology harnessing longitudinal real-world data, extracted from the electronic health records of a medical centre functioning as a clinical trial site, is demonstrated to develop an accurate analysis of the performance of CAR-T compared with the next-best treatment option, namely allogeneic haematopoietic cell transplant (HCT). Expand
Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Pediatric B-Cell Acute Lymphoblastic Leukemia.
TLDR
The long-term effectiveness of tisagenlecleucel is a critical but uncertain determinant of its cost effectiveness; however, if all patients ultimately require a transplantation to remain in remission, it will not be cost effective at generally accepted thresholds. Expand
Development of a Novel Anti-CD19 Chimeric Antigen Receptor: A Paradigm for an Affordable CAR T Cell Production at Academic Institutions
TLDR
It is shown that A3B1 CAR T cells are highly cytotoxic and specific against CD19+ cells in vitro, inducing secretion of pro-inflammatory cytokines and CAR T cell proliferation. Expand
A safe and potent anti-CD19 CAR T cell therapy
TLDR
Therapy with the new CD19-BBz(86) CAR T cells produces a potent and durable antilymphoma response without causing neurotoxicity or severe CRS, representing a safe and potent anti-CD19 CAR T cell therapy. Expand
...
1
2
3
4
5
...